New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance
- PMID: 19803707
- DOI: 10.1586/eri.09.67
New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance
Abstract
Different types of mycoses, especially invasive mycoses caused by yeasts and molds, are a growing problem in healthcare. The most notable explanation for this increase is a rise in the number of immunocompromised patients owing to advances in transplantation, the emergence of AIDS and a rise in the number of invasive surgical procedures. Despite advances in medical practice, some therapeutic problems remain. In addition, intrinsic or acquired antifungal resistance may pose a serious problem to antifungal therapy. A new generation of triazole agents (voriconazole, posaconazole, isavuconazole, ravuconazole and albaconazole) and the recent class of the echinocandins (caspofungin, micafungin and anidulafungin) have become available, and represent an alternative to conventional antifungals for serious fungal infection management. Currently, only two of the recent triazole generation (voriconazole and posaconazole) and all three echinocandins are available for clinical use. More precisely, voriconazole and posaconazole are indicated for the treatment of invasive fungal infections and the echinocandins for the treatment of specific candidiasis. Voriconazole and posaconazole have a very broad spectrum of antifungal activity that includes Candida species, and filamentous and dimorphic fungi. Their activity extends to both fluconazole- and itraconazole-resistant strains of Candida. A major difference between posaconazole and voriconazole is that posaconazole has activity against Zygomycetes including Mucor spp., Rhizopus spp. and Cunninghamella spp., and voriconazole has no activity against this class of fungi. Ravuconazole, isavuconazole and albaconazole have shown very potent in vitro activity against species of Candida, Cryptococcus and Aspergillus, and they are currently in various stages of development. All three echinocandin agents, caspofungin, micafungin and anidulafungin, are similar in their spectrum of activity. Echinocandins do not possess in vitro activity against important basidiomycetes, including Cryptococcus, Rhodotorula and Trichosporon. This review attempts to deliver the most up-to-date knowledge on the mode of action and mechanisms of resistance to triazoles and echinocandins in fungal pathogens. In addition, the in vitro activity data available on triazoles and echinocandins are reported.
Similar articles
-
In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.Rev Iberoam Micol. 2003 Dec;20(4):121-36. Rev Iberoam Micol. 2003. PMID: 15456349 Review.
-
New and emerging treatments for fungal infections.J Antimicrob Chemother. 2008 Jan;61 Suppl 1:i19-30. doi: 10.1093/jac/dkm428. J Antimicrob Chemother. 2008. PMID: 18063600 Review.
-
In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species.J Antimicrob Chemother. 2009 Jul;64(1):79-83. doi: 10.1093/jac/dkp138. Epub 2009 Apr 30. J Antimicrob Chemother. 2009. PMID: 19406849
-
Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.J Clin Microbiol. 2013 Aug;51(8):2571-81. doi: 10.1128/JCM.00308-13. Epub 2013 May 29. J Clin Microbiol. 2013. PMID: 23720791 Free PMC article.
-
Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).Diagn Microbiol Infect Dis. 2011 Jan;69(1):45-50. doi: 10.1016/j.diagmicrobio.2010.08.013. Diagn Microbiol Infect Dis. 2011. PMID: 21146713
Cited by
-
Pan-drug resistance and hypervirulence in a human fungal pathogen are enabled by mutagenesis induced by mammalian body temperature.Nat Microbiol. 2024 Jul;9(7):1686-1699. doi: 10.1038/s41564-024-01720-y. Epub 2024 Jun 19. Nat Microbiol. 2024. PMID: 38898217
-
Triazole Antifungal Quantification for Therapeutic Drug Monitoring in Serum by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS): Posaconazole, Voriconazole, Itraconazole, and Hydroxyitraconazole.Methods Mol Biol. 2024;2737:55-65. doi: 10.1007/978-1-0716-3541-4_6. Methods Mol Biol. 2024. PMID: 38036810
-
Polyelectrolyte-Complex-Based Hydrogel Inserts for Vaginal Delivery of Posaconazole and Probiotics.Gels. 2023 Oct 27;9(11):851. doi: 10.3390/gels9110851. Gels. 2023. PMID: 37998941 Free PMC article.
-
Mucormycosis in 2023: an update on pathogenesis and management.Front Cell Infect Microbiol. 2023 Sep 21;13:1254919. doi: 10.3389/fcimb.2023.1254919. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37808914 Free PMC article. Review.
-
Proteasome inhibition as a therapeutic target for the fungal pathogen Cryptococcus neoformans.Microbiol Spectr. 2023 Sep 26;11(5):e0190423. doi: 10.1128/spectrum.01904-23. Online ahead of print. Microbiol Spectr. 2023. PMID: 37750732 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous